Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00371475 · ClinicalTrials.gov registry record · Phase 3

A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions

A Phase 3 study, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 3
Development phase
150
Enrollment target

NCT00371475 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00371475, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 3
Development phase
150 participants
Enrollment target

Study Summary

TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results from patients treated with the TAXUS Liberté 38 mm stent to an historical TAXUS Express control. The control group is a case-matched, blended, long lesion subset population of TAXUS Express patients from the TAXUS IV and TAXUS V de novo clinical trials. The objective of the study is to evaluate clinical outcomes of TAXUS Liberté-SR 38 mm stent in de novo lesions and to assess the non-inferiority of TAXUS Liberté versus TAXUS Express. The TAXUS Liberté-SR stent is hypothesized to have comparable safety and efficacy to the TAXUS Express stent.

Interventions

  • DEVICE TAXUS Liberté-SR
  • DEVICE TAXUS™ Express

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2005-03
Est. Completion 2011-05
Phase Phase 3

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT00371475

The ClinicalTrials.gov registry entry for NCT00371475 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which TAXUS Liberté-SR is the first listed.

NCT00371475 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00371475 about?

NCT00371475 is a clinical study titled "A Study of the TAXUS Liberté Stent for the Treatment of Long De Novo Coronary Artery Lesions". TAXUS ATLAS is a global, multi-center, single-arm, non-inferiority trial comparing results from patients treated with the TAXUS Liberté 38 mm stent to an historical TAXUS Express control. The control group is a case-matched, blended, long lesion subset population of TAXUS Express patients from the T...

What is the current status of trial NCT00371475?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2005-03. Estimated completion is 2011-05.

What interventions are being tested in trial NCT00371475?

The interventions under investigation include: TAXUS Liberté-SR (DEVICE), TAXUS™ Express (DEVICE).

Who is sponsoring clinical trial NCT00371475?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.